COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses

COVID-19 免疫特征显示,尽管体液免疫反应下降,但抗病毒 T 细胞功能仍保持稳定。

阅读:5
作者:Agnes Bonifacius ,Sabine Tischer-Zimmermann ,Anna C Dragon ,Daniel Gussarow ,Alexander Vogel ,Ulrike Krettek ,Nina Gödecke ,Mustafa Yilmaz ,Anke R M Kraft ,Marius M Hoeper ,Isabell Pink ,Julius J Schmidt ,Yang Li ,Tobias Welte ,Britta Maecker-Kolhoff ,Jörg Martens ,Marc Moritz Berger ,Corinna Lobenwein ,Metodi V Stankov ,Markus Cornberg ,Sascha David ,Georg M N Behrens ,Oliver Witzke ,Rainer Blasczyk ,Britta Eiz-Vesper

Abstract

Cellular and humoral immunity to SARS-CoV-2 is critical to control primary infection and correlates with severity of disease. The role of SARS-CoV-2-specific T cell immunity, its relationship to antibodies, and pre-existing immunity against endemic coronaviruses (huCoV), which has been hypothesized to be protective, were investigated in 82 healthy donors (HDs), 204 recovered (RCs), and 92 active COVID-19 patients (ACs). ACs had high amounts of anti-SARS-CoV-2 nucleocapsid and spike IgG but lymphopenia and overall reduced antiviral T cell responses due to the inflammatory milieu, expression of inhibitory molecules (PD-1, Tim-3) as well as effector caspase-3, -7, and -8 activity in T cells. SARS-CoV-2-specific T cell immunity conferred by polyfunctional, mainly interferon-γ-secreting CD4+ T cells remained stable throughout convalescence, whereas humoral responses declined. Immune responses toward huCoV in RCs with mild disease and strong cellular SARS-CoV-2 T cell reactivity imply a protective role of pre-existing immunity against huCoV.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。